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Introduction {#cjp228-sec-0001}
============

The majority of intraoral squamous cell carcinomas (SCC) are located in the mobile tongue. Compared to tumours in other sites of the oral cavity, tongue SCCs more frequently metastasise to cervical lymph nodes and more than 30% of patients with tongue SCC have occult lymph node metastasis at the time of diagnosis, as confirmed by histology even if clinically undetectable [1](#cjp228-bib-0001){ref-type="ref"}. The high frequency of spread to lymph nodes is due to the dense lymphatic network present in the tongue, with most of the lymph fluid draining to lymph nodes in the submental and submandibular triangles (level I) and the upper jugular nodal group (level II). This rich lymphatic network also has connections across the midline, explaining why nodal metastasis can occur on both sides of the neck when the tumour is located in the midline of the tongue [1](#cjp228-bib-0001){ref-type="ref"}. The frequent spread to lymph nodes from the tongue emphasises the importance of early detection for successful treatment of tongue SCC.

Tumour cells can invade either as single cells or collectively. Epithelial‐to‐mesenchymal transition (EMT) is important in single cell invasion. During EMT, epithelial cells lose epithelial markers such as E‐cadherin and instead acquire mesenchymal characteristics including a migratory phenotype [2](#cjp228-bib-0002){ref-type="ref"}. The EMT process is regulated at the transcriptional, translational and post‐translational levels [3](#cjp228-bib-0003){ref-type="ref"}. The molecular and pathophysiological aspects of collective invasion are less well understood. A protein known to play a role in both EMT and collective invasion is podoplanin [4](#cjp228-bib-0004){ref-type="ref"}.

Podoplanin is a transmembrane glycoprotein involved in formation of lymph vessels [5](#cjp228-bib-0005){ref-type="ref"}. Apart from being expressed in endothelial cells in lymph vessels, podoplanin can be found in, for example, osteocytes and basal keratinocytes [5](#cjp228-bib-0005){ref-type="ref"} and also in some tumours with high invasive and metastatic potential, including squamous cell carcinomas of the head and neck (SCCHNs) [5](#cjp228-bib-0005){ref-type="ref"}. SCCHNs with high levels of podoplanin were reported to show significantly higher rates of lymph node metastasis, irrespective of the number of lymph vessels [6](#cjp228-bib-0006){ref-type="ref"}. This finding is of clinical relevance, as diagnostic biopsies are often of limited size and accordingly the number of lymph vessels can be hard to estimate, whereas expression of podoplanin in tumour cells can be easily calculated. Restriction of podoplanin expression to the periphery of tumour nests in SCCHN has also been shown to be an indicator of good prognosis [7](#cjp228-bib-0007){ref-type="ref"}. Specifically, looking at tongue SCC, the majority of tumours studied so far show high expression of podoplanin. High podoplanin expression has also been seen in the basal layer of hyperplastic and dysplastic lesions adjacent to SCCHN and interpreted as overexpression occurring early in head and neck tumourigenesis [6](#cjp228-bib-0006){ref-type="ref"}.

Here, we studied the prognostic impact of podoplanin in a large group of 129 tongue SCCs. We also measured the number of lymph vessels in the biopsies to clarify their impact on the clinical course of this disease.

Material and methods {#cjp228-sec-0002}
====================

Material {#cjp228-sec-0003}
--------

Formalin fixed, paraffin‐embedded biopsies from 129 patients with primary SCC of the tongue available at Umeå University Hospital and Naples, were included. Sixty‐five were men and 64 women. The mean age was 63.4 years, ranging from 19 to 93 years. The project was approved by the local Ethical Committee (dnr 01‐057, 03‐201).

The majority of patient samples had previously been analysed for expression of p16 and HPV16 [8](#cjp228-bib-0008){ref-type="ref"}. Follow up ranged between 1 and 179 months, with a mean of 46.6 months. All but seven patients had a follow up of 2 years or longer.

Status at the end of the study was staged as alive disease free, alive with disease, dead of disease, dead disease free or dead with disease, but not as first cause of death. Data on status were collected from the clinical files or, when not available there, from the Swedish Death Registry. For clinical data, see Table [1](#cjp228-tbl-0001){ref-type="table-wrap"}.

###### 

Results from scoring of podoplanin expression and number of lymph vessels in relation to age of the patient, N‐status and status at the end of the study

  Podoplanin      Age group   N‐status   Lymph vessels   Status                                   
  --------------- ----------- ---------- --------------- ---------- ---------- --- ---- ---- ---- ----
  **QS = 0**      2 (11%)     2 (4%)     4 (6%)          6 (6%)     2 (6%)     5   3    0    4    4
  **QS = 1‒5**    2 (11%)     19 (40%)   34 (53%)        41 (43%)   14 (42%)   0   38   17   32   23
  **QS = 6‒18**   14 (78%)    26 (56%)   26 (41%)        49 (51%)   17 (52%)   0   56   10   32   34
  129             18          47         64              96         33         5   97   27   68   61

QS = QuickScore (see text), ADF = alive disease free, DDF = dead disease free, AWD = alive with disease, DOD = dead of disease and DWD = dead with disease, but not as first cause of death.

Immunohistochemistry and scoring {#cjp228-sec-0004}
--------------------------------

An antibody detecting podoplanin (D2‐40; Abcam, Cambridge, UK) was diluted 1:25. Slides were pretreated in TRIS‐EDTA pH 8.0, and staining was performed in a Ventana staining machine according to the supplier\'s recommendations. The percentage of tumour cells expressing podoplanin as well as the intensity of staining was assessed. The percentage of tumour cells expressing podoplanin was divided into six groups, where 0--4% = 1, 5--19% = 2, 20--39% = 3, 40--59% = 4, 60--79% = 5 and 80--100% = 6. Staining intensity in turn was described as negative = 0, weak = 1, intermediate = 2 or strong = 3. By multiplying the score for percentage of podoplanin‐expressing tumour cells with the score for staining intensity, a quick score (QS) was calculated for each slide [9](#cjp228-bib-0009){ref-type="ref"}. Scoring of slides was performed independently by three of the authors (NS, ELJ and KN) and cases of disagreement were reevaluated and discussed to provide a consensus score.

The number of lymph vessels in each sample was scored between 0 and 3, with 0 being no lymph vessels detectable, 1 = few, 2 = moderate numbers and 3 = many lymph vessels detectable, respectively.

qRT/PCR {#cjp228-sec-0005}
-------

Twenty‐seven tongue SCCs, of which 23 had paired clinically normal tumour‐adjacent tissue samples and 14 tongue biopsies from healthy controls were included in the mRNA analysis. For example, in the case of a SCC on the left border of the tongue, clinically normal tumour‐adjacent tissue was taken from the right side of the tongue. For clinical data on the tumours, see Table [2](#cjp228-tbl-0002){ref-type="table-wrap"}. Paraffin‐embedded samples from 10 of these tongue SCC were included in the protein analysis. Samples previously analysed [10](#cjp228-bib-0010){ref-type="ref"} had been homogenized in trizol and total RNA was extracted using either chloroform or an RNA/protein purification kit (Norgen). The remaining samples were homogenized in lysis buffer from All Prep DNA/RNA/miRNA Universal Kit (Qiagen) using Precellys (Bertin technologies). After dilution in water, no difference in RNA quality or yield was observed between the different methods according to measurement with nano‐drop and bioanalyzer. For cDNA synthesis, 500 ng of total RNA was used with RevertAid H minus first strand cDNA synthesis kit (Thermo Scientific). cDNA was diluted 5× and 2.5 µl used in each reaction with a total reaction volume of 10 µl. For PCR amplification of cDNA, IQ sybr green supermix (Bio‐Rad) was used in combination with primers for podoplanin (Bio‐Rad assay ID qHSaCID 0009013) and reference primers: GAPDH, UBC, LAD1, RPS12 from PrimerDesign Ltd. For GAPDH and UBC the company does not give out sequences. LAD1 (For: CCTCCCACCCGTCACACT, Rev: CTGCTGTAGGTTCGCTGTGT), RPS12 (For: TGCTGCTGGAGGTGTAATGG, Rev:GCACACAA AGATGGGCTTGG.

###### 

Clinical data on 27 tumours included in the analysis of podoplanin mRNA

  Nr                                         Sex      Age   Localisation   TNM
  ------------------------------------------ -------- ----- -------------- ---------
  20                                         Male     61    1              T1N0M0
  35[\*](#cjp228-note-0004){ref-type="fn"}   Female   24    2              T2N0M0
  40                                         Female   81    3              T4N2bM0
  49[\*](#cjp228-note-0004){ref-type="fn"}   Female   52    3              T4N2cM0
  51[\*](#cjp228-note-0004){ref-type="fn"}   Male     74    1              T2N0M0
  56                                         Female   41    3              T2N2bM0
  58[\*](#cjp228-note-0004){ref-type="fn"}   Male     61    1              T1N0M0
  59[\*](#cjp228-note-0004){ref-type="fn"}   Female   68    1              T2N0M0
  61                                         Male     70    3              T4aN0M0
  65[\*](#cjp228-note-0004){ref-type="fn"}   Female   81    3              T2N0M0
  68                                         Male     62    1              T2N0M0
  70[\*](#cjp228-note-0004){ref-type="fn"}   Male     71    2              T1N0M0
  73                                         Male     81    3              T4aN0M0
  76                                         Male     59    3              T4aN0M0
  79                                         Male     61    2              T1N0M0
  82[\*](#cjp228-note-0004){ref-type="fn"}   Female   19    1              T4N0M0
  83[\*](#cjp228-note-0004){ref-type="fn"}   Female   64    2              T1N0M0
  85[\*](#cjp228-note-0004){ref-type="fn"}   Female   87    1              T2N0M0
  92                                         Female   63    2              T2N0M0
  98                                         Male     31    3              T2N0M0
  105                                        Male     64    2              T1N0M0
  111                                        Female   31    2              T1N0M0
  119                                        Male     66    2              T2N0M0
  124                                        Male     54    3              T4N2bM0
  131                                        Female   74    2              T2N0M0
  137                                        Female   71    2              T2N0M0
  138                                        Male     50    1              T2N1M0

For tumour localisation 1 = tongue, 2 = border of tongue and 3 = overgrowth into floor of mouth.

Tumours labelled with \* also had paraffin samples included in the protein analysis. TNM = T(umour), N(odes), M(etastasis).

Cycling conditions: enzyme activation at 95°C for 3 min, denaturation at 95°C for 15 s and annealing at 60°C for 60 s. The process was run for 40 cycles.

To normalize the values, a geometric mean from the reference genes GAPDH, UBC, RPS12 and LAD1 was used in the calculation of 2^−ΔCq^.

Statistical analysis {#cjp228-sec-0006}
--------------------

SPSS version 22 was used for statistical analysis, correlating results from scoring of podoplanin to clinical data. The Chi square test was used for calculation of *p*‐values and a *p*‐value \<0.05 was considered statistically significant. Two‐ and 5‐year survival were used in the survival analysis. Mann‐Whitney test was used to analyse mRNA levels.

Results {#cjp228-sec-0007}
=======

Clinical data {#cjp228-sec-0008}
-------------

At 2‐year follow up, which was available for 122 of the 129 patients studied, 75 were alive and 47 dead. Considering age, 56% of patients ≤40 years were alive 2 years after diagnosis, in contrast to 73% of patients aged 41--65, but similar to 54% of patients \>65 years. At 5 years (follow up available for 101 patients of whom 48% were alive), 39% of patients ≤40 years were alive, in contrast to 65% of those aged 41--65 years but similar to 37% of patients \>65 (*p* = 0.009). For status at the end of the study, see Table [1](#cjp228-tbl-0001){ref-type="table-wrap"}.

Expression of podoplanin {#cjp228-sec-0009}
------------------------

Of the 129 tongue SCC samples, 8 (6%) were negative for podoplanin, 55 (43%) showed low expression (QS 1--5) and 66 (51%) showed high expression (QS 6--18) (Figure [1](#cjp228-fig-0001){ref-type="fig"}). A significantly higher percentage of tumours in patients aged ≤40 years (78%) showed high expression of podoplanin (QS = 6--18), compared to 56% and 41% of the 41--65 and \>65‐year‐old patients, respectively (*p* = 0.027) (Table [1](#cjp228-tbl-0001){ref-type="table-wrap"}).

![(A--C) Representative podoplanin immunohistochemistry in tongue SCC with different QuickScores (QS), as indicated. (D) Podoplanin‐expressing tumour cells showing perineural growth.](CJP2-2-03-g001){#cjp228-fig-0001}

Looking at the whole group of patients, there was no significant association between expression of podoplanin (QS), N‐status, T‐status, gender or localisation.

Lymph vessels were detectable in all but five samples, with 52% showing a moderate number. The five samples lacking detectable lymph vessels were also negative for podoplanin in the tumour tissue. Of the 94 samples with a lymph vessel score of 2 or 3, all but two expressed podoplanin. No significant association was seen between the presence of lymph vessels, age, gender, T‐ or N‐stage or status at the end of the study (Table [1](#cjp228-tbl-0001){ref-type="table-wrap"}).

Levels of podoplanin mRNA {#cjp228-sec-0010}
-------------------------

All 27 tumours analysed showed significantly higher levels of podoplanin mRNA compared to both healthy controls, and clinically normal tongue tissue adjacent to the tumours (*p* \< 0.0001). In the group of tumour‐adjacent tongue tissue, levels were also significantly higher compared to healthy normal tongue (*p* = 0.005). Inter‐individual variation in podoplanin levels was seen in tumours, with the highest levels seen in two females, one 24 years old (no 35) and the other 41 years old (no 56) (Figure [2](#cjp228-fig-0002){ref-type="fig"}).

![Top: Mean levels of podoplanin mRNA in 27 tongue SCCs (T), 23 matched clinically normal tongue samples adjacent to tumour (N) and 14 tongue samples from healthy controls (C). \*\*\*\**p* \< 0.0001, \*\**p* = 0.005. The levels of podoplanin mRNA in individual patients, matched clinically normal tongue adjacent to tumour and normal tongue from healthy controls are shown in the lower panel.](CJP2-2-03-g002){#cjp228-fig-0002}

Discussion {#cjp228-sec-0011}
==========

Tongue SCC is a severe disease, which shows an increase worldwide, especially among young people and particularly women [11](#cjp228-bib-0011){ref-type="ref"}. The disease may have an unpredictable outcome and the known worse prognosis for young patients [8](#cjp228-bib-0008){ref-type="ref"}, [12](#cjp228-bib-0012){ref-type="ref"} was also clearly seen in the present material, where only 39% of patients ≤40 years were alive after 5 years compared to 65% of those aged 41--65 years.

One of the biggest challenges with tongue SCC is that 30% of clinically node negative tumours have occult lymph node metastasis at diagnosis [1](#cjp228-bib-0001){ref-type="ref"}. However, without performing a staging neck dissection it is not possible to pinpoint these 30%. The tongue, with its well‐developed lymphatic network, is ideal for easy spread of tumour cells and, as N‐status is a factor of known prognostic significance, it would be valuable to identify at the time of diagnosis factors that can aid in, or precede development of, nodal spread.

A factor of potential importance in this aspect is the lymph vessel‐specific glycoprotein podoplanin. Previous results concerning its role in tumour spread are contradictory, where some claim that it induces EMT [13](#cjp228-bib-0013){ref-type="ref"} whereas others instead show that it forms filopodia and in that way induces collective cell migration [14](#cjp228-bib-0014){ref-type="ref"}.

Podoplanin expression has been reported in mucosa adjacent to SCC [15](#cjp228-bib-0015){ref-type="ref"} and this has been interpreted to indicate that the protein is expressed early in the tumourigenic process [16](#cjp228-bib-0016){ref-type="ref"}. Our results from mRNA analysis support this interpretation as levels of podoplanin in clinically normal tongue adjacent to tumour were significantly higher than those in normal tongue taken from healthy volunteers with no evidence of SCC or other disease. Levels in tongue SCC were also significantly higher compared to both groups. At the protein level, there was no tendency for lowered expression in later stages of the tumourigenic process. On the contrary, 61% of N+ tumours showed high podoplanin expression, judged as QS 6--18, compared to 51% of N0 tumours. Although the number of cases are low, none of the eight podoplanin negative tumours was T4, whereas seven of them were T1 and T2.

Our figures for podoplanin expression with 6% negative, 43% low expressing (QS 1--5) and 51% high expressing (QS 6--18) tumours are comparable to the findings of Yuan and coworkers [6](#cjp228-bib-0006){ref-type="ref"}. In contrast to their findings and also to another study [16](#cjp228-bib-0016){ref-type="ref"}, we found no association between high expression of podoplanin and lymph node metastasis or prediction of poorer outcome. In Yuan\'s material, 89% of the 28 N+ tongue SCC showed high levels of podoplanin, compared to 52% of our 33 N+ tumours. As the scales for evaluating percentage of podoplanin‐expressing tumour cells differ between the two studies, it is not possible to fully compare these results. Bartuli *et al* [17](#cjp228-bib-0017){ref-type="ref"} analysed a mixed group of 20 SCC, of which only 12 were located in the tongue compared to our group of 129 tongue SCCs. A limited group of 12 tumours may thus not be representative of the whole group of tongue SCCs.

As has been seen previously, patients ≤40 years are a specific group and, in this study, showed the significantly highest percentage of high podoplanin‐expressing tongue tumours. Even if there was no difference in outcome for these young patients with high podoplanin expression, it is noteworthy that this group, once again, differs from the majority of patients with tongue SCC, who are typically much older.

Concerning the number of lymph vessels, no association with any clinical factor was seen. It must, however, be emphasized that the calculation of lymph vessel number in diagnostic biopsy material is not optimal and not representative of all aspects of the whole tumour. Thus, the potential relevance of lymph vessel numbers cannot be excluded based on the present results.

In summary, we have measured podoplanin levels at both protein and mRNA level in tongue SCC and found significantly higher levels in tumours compared to normal tongue as well as to clinically normal tongue in the tumour vicinity. In contrast to other studies, we could not confirm the correlation seen between podoplanin levels and the presence or absence of lymph node metastases. However, we show that tongue SCC arising in patients ≤40 years of age has the significantly highest percentage of high podoplanin expressing tumours. The clinical value of this finding remains to be determined but suggests that targeting podoplanin with antibodies or lectins [18](#cjp228-bib-0018){ref-type="ref"} could be particularly useful for the group of young patients with tongue SCC.
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